Kahira Pharmaceuticals & Chemical Industries Company (EGX:CPCI)
Egypt · Delayed Price · Currency is EGP 267.26
-1.55 (-0.58%)
At close: Jan 12, 2026
EGX:CPCI Income Statement
Financials in millions EGP. Fiscal year is July - June.
Millions EGP. Fiscal year is Jul - Jun.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2016 - 2020 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 | 2016 - 2020 |
| 2,310 | 2,079 | 1,361 | 1,005 | 1,112 | 1,062 | Upgrade | |
Revenue Growth (YoY) | 59.59% | 52.80% | 35.38% | -9.61% | 4.71% | 5.11% | Upgrade |
Cost of Revenue | 1,424 | 1,288 | 843.19 | 767.94 | 785.17 | 793.91 | Upgrade |
Gross Profit | 886.2 | 791.47 | 517.66 | 237.3 | 326.95 | 268.13 | Upgrade |
Selling, General & Admin | 134.35 | 138.06 | 116.67 | 103.71 | 101.75 | 87.62 | Upgrade |
Other Operating Expenses | 96.36 | 85.54 | 115.32 | 56.85 | 33.11 | 24.18 | Upgrade |
Operating Expenses | 230.71 | 223.6 | 231.99 | 160.56 | 134.86 | 111.8 | Upgrade |
Operating Income | 655.49 | 567.86 | 285.67 | 76.74 | 192.08 | 156.33 | Upgrade |
Interest Expense | -16.09 | -13.54 | -18.94 | -3.47 | - | - | Upgrade |
Interest & Investment Income | 23.69 | 21.71 | 14.68 | 4.36 | 6.87 | 3.89 | Upgrade |
Currency Exchange Gain (Loss) | -13.79 | -12.74 | 27.81 | 45.83 | - | - | Upgrade |
Other Non Operating Income (Expenses) | 10.2 | 9.13 | 6.13 | 4.01 | 15.14 | 2.84 | Upgrade |
EBT Excluding Unusual Items | 659.49 | 572.43 | 315.35 | 127.48 | 214.1 | 163.06 | Upgrade |
Gain (Loss) on Sale of Assets | 2.22 | 2.22 | -0 | 0.08 | - | - | Upgrade |
Pretax Income | 661.71 | 574.64 | 315.35 | 127.56 | 214.1 | 163.06 | Upgrade |
Income Tax Expense | 148.66 | 130.92 | 69.24 | 30.47 | 48.35 | 38.75 | Upgrade |
Earnings From Continuing Operations | 513.05 | 443.72 | 246.11 | 97.09 | 165.74 | 124.3 | Upgrade |
Net Income | 513.05 | 443.72 | 246.11 | 97.09 | 165.74 | 124.3 | Upgrade |
Net Income to Common | 513.05 | 443.72 | 246.11 | 97.09 | 165.74 | 124.3 | Upgrade |
Net Income Growth | 96.36% | 80.29% | 153.48% | -41.42% | 33.34% | 13.89% | Upgrade |
Shares Outstanding (Basic) | 15 | 15 | 15 | 15 | 15 | 15 | Upgrade |
Shares Outstanding (Diluted) | 15 | 15 | 15 | 15 | 15 | 15 | Upgrade |
EPS (Basic) | 34.35 | 29.71 | 16.48 | 6.50 | 11.10 | 8.32 | Upgrade |
EPS (Diluted) | 34.35 | 29.71 | 16.48 | 6.50 | 11.10 | 8.32 | Upgrade |
EPS Growth | 96.14% | 80.29% | 153.48% | -41.42% | 33.34% | 13.89% | Upgrade |
Free Cash Flow | 293.66 | 239.25 | 46.65 | 9.45 | 34.52 | 138.57 | Upgrade |
Free Cash Flow Per Share | 19.66 | 16.02 | 3.12 | 0.63 | 2.31 | 9.28 | Upgrade |
Dividend Per Share | - | 16.740 | 12.830 | 5.000 | 5.000 | 4.000 | Upgrade |
Dividend Growth | - | 30.48% | 156.60% | - | 25.00% | 49.25% | Upgrade |
Gross Margin | 38.36% | 38.06% | 38.04% | 23.61% | 29.40% | 25.25% | Upgrade |
Operating Margin | 28.37% | 27.31% | 20.99% | 7.63% | 17.27% | 14.72% | Upgrade |
Profit Margin | 22.21% | 21.34% | 18.09% | 9.66% | 14.90% | 11.70% | Upgrade |
Free Cash Flow Margin | 12.71% | 11.51% | 3.43% | 0.94% | 3.10% | 13.05% | Upgrade |
EBITDA | 692.36 | 599.51 | 290.99 | 88.3 | 207.25 | 156.77 | Upgrade |
EBITDA Margin | 29.97% | 28.83% | 21.38% | 8.78% | 18.64% | 14.76% | Upgrade |
D&A For EBITDA | 36.87 | 31.65 | 5.32 | 11.56 | 15.17 | 0.44 | Upgrade |
EBIT | 655.49 | 567.86 | 285.67 | 76.74 | 192.08 | 156.33 | Upgrade |
EBIT Margin | 28.37% | 27.31% | 20.99% | 7.63% | 17.27% | 14.72% | Upgrade |
Effective Tax Rate | 22.46% | 22.78% | 21.96% | 23.88% | 22.58% | 23.77% | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.